EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent
Portfolio Pulse from Vandana Singh
Adial Pharmaceuticals Inc (NASDAQ:ADIL) has been granted a US patent (number 11957664) for a combination of its proprietary genetic diagnostic and its lead investigational drug, AD04, for treating alcohol use disorder (AUD) and other drug dependencies such as opioid use disorder (OUD). This patent strengthens Adial's intellectual property portfolio, covering specific genotypes for targeted treatment. The addressable market for these treatments in the U.S. is estimated at $40 billion. Additionally, Adial has previously received a patent for AD04 targeting the serotonin transporter gene for potential OUD treatment and published positive clinical results and safety profiles for AD04.
April 22, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adial Pharmaceuticals Inc receives a US patent for its AUD and OUD treatment, potentially tapping into a $40 billion market.
The granting of a new US patent to Adial Pharmaceuticals for its combination treatment for AUD and OUD significantly enhances the company's intellectual property portfolio, potentially increasing its market value and investor interest. The identification of specific genotypes for targeted treatment and the addressable market size of $40 billion in the U.S. alone are likely to be viewed positively by investors, potentially leading to a short-term increase in ADIL's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100